Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Biomind Labs Inc. N.BMND

Alternate Symbol(s):  BMNDF

Biomind Labs Inc. is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. The Company’s focus is to guarantee patients access to affordable and modern day treatments and use cases.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NEO:BMND)

Fundamentals Snapshot (NEO:BMND)

Current News (NEO:BMND)

Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer's Disease With a Proprietary formulation Based On 5-MeO-DMT

Business Wire April 25, 2023

Biomind Labs Reaches High Purity and Yield of DMT Through an Optimized Extraction Method for Its New Chemical Entity Triptax(TM)

Business Wire March 31, 2023

Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer's Disease

Business Wire December 28, 2022

Biomind Labs Announces FDA Investigational New Drug Clearance for Its New Chemical Entity Triptax(TM) Targeting Treatment-Resistant Depression and Reports Third Quarter Financial Results

Business Wire November 14, 2022

Biomind Labs (NEO:BMND) sees positive results from its phase 2 depression treatment trial

Jon Brown November 4, 2022

Biomind Labs Announces Positive Initial Results From Its Phase II Trial on Its BMND01 Candidate for Treatment Resistant Depression

Business Wire November 4, 2022

Biomind Labs Announces Pre-IND Meeting Request Granted by FDA for Its New Chemical Entity Triptax(TM) Targeting Treatment-Resistant Depression

Business Wire October 11, 2022

Biomind Labs and Queen's University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System

Business Wire September 27, 2022

Biomind Labs (NEO:BMND) completes phase II DMT trial

Caroline Egan  September 21, 2022

Opinion & Analysis (NEO:BMND)

No current opinion is available.

Bullboard Posts (NEO:BMND)

Files International Patent Application on Its DMT Candidates

September 28, 2021 07:00 AM Eastern Daylight Time TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the...
Betteryear2 - September 28, 2021

CWI On Watch Zone

Keep a close eye on CWI @ current levels. Here is the link to what to look at: https://bit.ly/2tvzGCH
Kaiden23 - June 22, 2018

anybody following this company?

Trying to get a sense if there are any shareholders outside of the large insider block?
Roma1927 - October 16, 2017

I was right, sit back, relax and rally behind gains, $3 targ

-i'm setting a $3 price target for this stock -i'm not always right but i do know that the quarterly earnings which for the first...
suitman87 - April 1, 2017

Excited for quarterly earnings

-insider stock ownership signals solid growth -we are at a low now and i am expecting a high by quarterly earnings -this company is too...
suitman87 - March 18, 2017

News today and drop in share price

this is a extremely volitile stock so this is expected (10% drop) this likley occoured after the company sold many cheap shares to...
suitman87 - March 2, 2017